Introduction to OxyContin OC 30mg
OxyContin OC 30mg is anΒ extended-release oxycodone formulationΒ classified as aΒ Schedule II controlled substance. This intermediate-strength version of the original OxyContin (pre-2010 reformulation) is designed forΒ management of moderate to severe chronic pain in opioid-tolerant patients. The “OC” designation indicates itΒ lacks modern abuse-deterrent properties, making it particularly high-risk for misuse compared to current “OP” formulations.
Oxycontin OC 30mg
OxyContin OC 30mg is a prescription opioid medication that contains oxycodone, used for managing moderate to severe chronic pain. The “OC” formula refers to the original controlled-release version, designed to deliver consistent pain relief over an extended period, making it ideal for patients who need continuous, long-lasting pain management.
OxyContin OC 30mg is often prescribed to individuals who require around-the-clock pain control and have not found relief with other pain medications. However, due to its strength and potential for misuse, it should only be used under the strict supervision of a healthcare provider.
Key Benefits:
- Provides long-lasting pain relief with controlled-release technology
- Effective for managing moderate to severe chronic pain
- Ideal for continuous pain management over 12 hours
Important Considerations:
- Risk of addiction, overdose, and misuse
- Common side effects include constipation, nausea, and drowsiness
- Avoid alcohol and certain medications that interact with opioids
Consult your doctor to see if OxyContin OC 30mg is the right option for your pain management.
Medical Uses & Indications
FDA-Approved Uses
β
Β Moderate to severe chronic painΒ requiring continuous opioid therapy
β
Β Cancer pain managementΒ in opioid-tolerant patients
β
Β Pain uncontrolled by immediate-release opioids
Key Clinical Features
β’Β Formulation:Β Original controlled-release (non-abuse deterrent)
β’Β Onset:Β 1-2 hours
β’Β Duration:Β 12-hour controlled release
β’Β Equianalgesic ratio:Β 30mg q12h β 45mg oral morphine daily
β’Β DEA Classification:Β Schedule II (Highest abuse potential)
Pharmacology & Mechanism
Neurochemical Action
β’ Full ΞΌ-opioid receptor agonist
β’ ΞΊ-opioid receptor partial agonist
β’ Sustained activation of pain modulation pathways
Metabolic Profile
β’Β Hepatic metabolism:Β CYP3A4 (major), CYP2D6 (minor)
β’Β Active metabolites:Β Oxymorphone (via CYP2D6)
β’Β Elimination half-life:Β 4.5-8 hours (ER formulation)
Dosing & Administration
Strict Eligibility Criteria
β’Β Confirmed opioid tolerance:Β β₯60mg oral morphine equivalent daily
β’Β Stable pain patternΒ (Not episodic/breakthrough)
β’Β Failed trials of lower-dose opioids
Conversion Protocol
-
Calculate total daily morphine equivalent
-
Reduce by 25-50% (incomplete cross-tolerance)
-
Divide by 2 for q12h dosing
Critical Safety Notes
β Β Hospital initiation recommended
β Β Never crush/chew tabletsΒ (immediate 30mg release risk)
β Β Requires dual prescriber verification in some states
β Β Naloxone rescue kit mandatory
Safety Profile
Common Adverse Effects
β’ Constipation (universal, requires prophylaxis)
β’ Nausea/vomiting (30-40%)
β’ Sedation/dizziness
β’ Pruritus (20-25%)
Black Box Warnings
βΒ High potential for addiction and abuse
βΒ Life-threatening respiratory depression
βΒ Accidental ingestion danger
βΒ Concomitant CNS depressant risk
Risk Mitigation Strategies
Prescribing Safeguards
-
Documented failure of abuse-deterrent formulations
-
Written opioid treatment agreement
-
Weekly follow-upsΒ for first 3 months
-
Random urine drug screening
Patient Safety Measures
β’Β Biometric locked storage
β’Β Mandatory caregiver training
β’Β Medication disposal protocol
β’Β Absolute alcohol prohibition
Clinical Alternatives
For Chronic Pain
β’Β OxyContin OP (abuse-deterrent formulation)
β’Β Xtampza ER (abuse-deterrent oxycodone)
β’Β Morphine sulfate ER
Non-Opioid Options
β’Β DuloxetineΒ (For neuropathic pain)
β’Β Gabapentin enacarbil
β’Β Interventional pain procedures
Special Population Considerations
| Population | Dosing Adjustment | Monitoring |
|---|---|---|
| Elderly (β₯65) | CONTRAINDICATED | – |
| Hepatic impairment | CONTRAINDICATED | – |
| Renal (CrCl<30) | CONTRAINDICATED | – |
| Pediatric | CONTRAINDICATED | – |
Reviews
There are no reviews yet.